Bicara Therapeutics (BCAX) Expected to Announce Quarterly Earnings on Tuesday

Key Points

• Q1 2026 earnings: Bicara is set to report Q1 2026 results before the market opens on May 12, with analysts forecasting EPS of ($0.64) and an earnings call scheduled for May 11 at 8:30 AM ET.
• Insiders and institutions: Insiders sold 174,310 shares worth about $3.46M in the last quarter (including CFO transactions under 10b5-1 plans), while large institutions like T. Rowe Price, Vestal Point, Janus Henderson and State Street significantly increased positions, indicating heavy institutional inflows.
• Market view and stock metrics: The stock is trading near $22.49 with a market cap of $1.48B and a 52-week range of $7.80–$24.25; analysts rate the name a "Moderate Buy" with an average price target of $28 (8 Buys, 3 Holds, 1 Sell) despite expected FY EPS of about -$3.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) is projected to post its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect Bicara Therapeutics to post earnings of ($0.64) per share for the quarter. Individuals can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Monday, May 11, 2026 at 8:30 AM ET.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last issued its earnings results on Monday, March 30th. The company reported ($0.68) EPS for the quarter, beating analysts' consensus estimates of ($0.72) by $0.04. On average, analysts expect Bicara Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Bicara Therapeutics Stock Performance

NASDAQ BCAX traded down $0.23 during trading hours on Tuesday, reaching $22.49. The stock had a trading volume of 108,070 shares, compared to its average volume of 514,323. The stock has a fifty day moving average of $20.08 and a 200 day moving average of $17.89. The stock has a market cap of $1.48 billion, a P/E ratio of -8.84 and a beta of -0.57. Bicara Therapeutics has a 52-week low of $7.80 and a 52-week high of $24.25.

Insider Buying and Selling

In other Bicara Therapeutics news, CFO Ivan Hyep sold 9,200 shares of the company's stock in a transaction that occurred on Tuesday, April 21st. The stock was sold at an average price of $23.00, for a total value of $211,600.00. Following the sale, the chief financial officer owned 145,355 shares in the company, valued at approximately $3,343,165. This represents a 5.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider David Raben sold 5,500 shares of the company's stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $22.88, for a total value of $125,840.00. Following the completion of the sale, the insider owned 55,286 shares in the company, valued at approximately $1,264,943.68. This represents a 9.05% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 174,310 shares of company stock worth $3,459,283.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in BCAX. T. Rowe Price Investment Management Inc. lifted its position in shares of Bicara Therapeutics by 596.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company's stock valued at $54,472,000 after buying an additional 2,771,868 shares in the last quarter. Janus Henderson Group PLC purchased a new position in shares of Bicara Therapeutics during the 4th quarter valued at approximately $44,484,000. Vestal Point Capital LP lifted its position in shares of Bicara Therapeutics by 80.6% during the 2nd quarter. Vestal Point Capital LP now owns 5,000,000 shares of the company's stock valued at $46,450,000 after buying an additional 2,231,025 shares in the last quarter. Franklin Resources Inc. purchased a new position in shares of Bicara Therapeutics during the 4th quarter valued at approximately $27,265,000. Finally, State Street Corp lifted its position in shares of Bicara Therapeutics by 179.5% during the 4th quarter. State Street Corp now owns 1,649,537 shares of the company's stock valued at $27,762,000 after buying an additional 1,059,260 shares in the last quarter.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. HC Wainwright upped their target price on Bicara Therapeutics from $40.00 to $42.00 and gave the company a "buy" rating in a research report on Tuesday, March 31st. Wedbush reiterated an "outperform" rating and issued a $30.00 target price on shares of Bicara Therapeutics in a research report on Tuesday, March 31st. The Goldman Sachs Group upped their price objective on Bicara Therapeutics from $14.00 to $16.00 and gave the stock a "neutral" rating in a research report on Tuesday, March 31st. BTIG Research restated a "buy" rating on shares of Bicara Therapeutics in a research report on Thursday, January 15th. Finally, Wells Fargo & Company upped their price objective on Bicara Therapeutics from $11.00 to $16.00 and gave the stock an "equal weight" rating in a research report on Tuesday, March 31st. Eight investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $28.00.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company's research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company's lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.